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More than 40% of the body mass is represented by muscle tissue, which possesses the
innate ability to regenerate after damage through the activation of muscle-specific stem
cells, namely satellite cells. Muscle diseases, in particular chronic degenerative states of
skeletal muscle such as dystrophies, lead to a perturbation of the regenerative process,
which causes the premature exhaustion of satellite cell reservoir due to continuous cycles
of degeneration/regeneration. Nowadays, the research is focused on different therapeutic
approaches, ranging from gene and cell to pharmacological therapy, but still there is no
definitive cure in particular for genetic muscle disease. Keeping this in mind, in this article,
we will give special consideration to muscle diseases and the use of fetal derived stem
cells as a new approach for therapy. Cells of fetal origin, from cord blood to placenta and
amniotic fluid, can be easily obtained without ethical concern, expanded and differentiated
in culture, and possess immune-modulatory properties. The in vivo approach in animal
models can be helpful to study the mechanism underneath the operating principle of the
stem cell reservoir, namely the niche, which holds great potential to understand the onset
of muscle pathologies.
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INTRODUCTION
The muscular dystrophies are heterogeneous genetic diseases that
strongly impair skeletal muscle structure and function. These
disorders are caused by mutations in genes encoding for struc-
tural proteins essential for muscle integrity, and depending on the
alteration, it is possible to distinguish dystrophies due to (i) muta-
tions on a specific gene, such as Duchenne muscular dystrophy
(DMD) or on distinct genes, e.g., limb-girdle muscular dystrophies
(LGMD); (ii) epigenetic alterations, for instance facioscapulo-
humeral muscular dystrophy; and (iii) repeat expansion, such as
myotonic dystrophy. The primary genetic defect results in a wide
range of pathological phenotypes, different for fashion of inheri-
tance, age of onset, severity and distribution of muscle weakness,
and speed of progression (Leung and Wagner, 2013).
In particular, DMD is the most prevalent and severe dystro-
phy that affects skeletal muscle. It is an X-linked recessive disease
due to mutations on dystrophin gene, which determines the pro-
duction of a truncated and non-functional protein. Dystrophin
functions as a muscle fiber stabilizer by linking the cytoplasmic
actin filaments with the extracellular matrix. The DMD mus-
cle is characterized by continuous fiber damage, which results in
an altered regenerative turnover thus leading to the premature
exhaustion of muscle stem cell compartment, the development of
chronic inflammation, and the infiltration of adipose and fibrotic
tissues. In DMD patients, the muscle loss begins very early in
childhood starting from lower extremities and leading to progres-
sive difficulty with walking, and finally, up to the confinement in a
wheelchair. In addition to loss of mobility, the major disabling co-
morbidities are represented by heart disease and respiratory failure
that are the most common causes of death (Wilschut et al., 2012;
Kharraz et al., 2014). In 1984, Bulfield and co-workers described
an X chromosome-linked mutant mouse, also called mdx, which
mimics the human DMD showing elevated plasma levels of mus-
cle creatine kinase and pyruvate kinase and histological lesions
characteristic of muscular dystrophies, although with a milder
phenotype (Bulfield et al., 1984). In 2010, Sacco et al. (2010) cre-
ated a new mouse model where mdx mutation was associated
with the loss of telomerase (mTR) activity. Indeed, these double-
knockout mice display a more severe as well as rapidly progressing
phenotype and a greatly reduced life span. In order to allow human
cell transplantation for preclinical studies, immunocompromised
mdx mouse strains have been created, such asmdx nude mice (Par-
tridge et al., 1989) and NOD/Rag1nullmdx5cv mice (Lapan et al.,
2012).
Limb-girdle muscular dystrophies are a family of diseases
affecting mainly proximal muscle, in particular shoulders, upper
arms, pelvic area, and thighs. These disorders are caused by muta-
tion in various genes encoding muscle structural proteins and
present different inheritance patterns; therefore, they consistently
differ in terms of age of onset, progress, and severity of disease
(Mitsuhashi and Kang, 2012). There are many mouse models for
LGMD, according to the variety of involved genes and genetic
defects that result in this family of muscle dystrophies. For exam-
ple, knockout mice for α-sarcoglycan gene accurately resemble the
LGMD-2D phenotype (Duclos et al., 1998), a deletion on dys-
ferlin gene produces a LGMD-2B phenotype in SJL-Dysf mice
(Bittner et al., 1999), while mice carrying mutations on myotilin
gene develop the autosomal dominant LGMD-1A (Liu et al., 2014).
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Beside these muscle-specific diseases, there are pathologies that
arise from other tissues and consequently affect skeletal muscle.
Since the close interplay between nervous system and skeletal mus-
cle compartment, many of these disorders are related to neural
degeneration, which causes muscle loss. One example is spinal
muscular atrophy (SMA), an autosomal recessive disorder charac-
terized by degeneration of anterior horn neurons and consequent
muscle weakness and atrophy. The incidence of SMA is about one
in 10,000 live births. It was first described at the end of nine-
teenth century and only 100 years later the genetic defect was
found and localized in the chromosome 5 cared by survival motor
neuron (SMN ) gene (Gilliam et al., 1990; Lefebvre et al., 1995).
In humans, there are normally two copies of SMN gene, SMN1
is essential to the pathogenesis, while the number of copies of
SMN2 determines the severity of the disease (Lorson et al., 1998;
Feldkotter et al., 2002). Different strategies have been deployed to
create murine model of SMA, and using the cre-loxP system the
loss of function of Smn gene has been directed toward specific
tissues, in particular to skeletal muscle. The mouse model HSA-
Cre, SmnF7/F7 allows to evaluate the effect of Smn knockout on
muscle since the Cre-recombinase is placed under the control of
alpha skeletal actin (Nicole et al., 2003). For this reason, mutant
mice display pathological features that mimic a muscle dystrophy
phenotype, such as muscle weakness and atrophy and chest defor-
mation with consequent respiratory failure (Cifuentes-Diaz et al.,
2001; Salah-Mohellibi et al., 2006).
The research is currently focused on three main therapeutic
approaches for muscle diseases. Gene therapy aims to restore the
dystrophin protein complex through different strategies, ranging
from the development of new vectors capable of delivering effi-
ciently the missing gene to the postmitotic nuclei of the muscle
fibers, to exon skipping and the enhancement of the synthesis
of proteins such as utrophin. The pharmacological approach is
mainly focused on the attenuation of the inflammation (corti-
costeroids administration) and the treatment of co-morbidities
(cardiomyopathy, osteoporosis, respiratory failure). Nowadays,
new compounds modulating muscle-specific neuronal nitric oxide
synthase (nNOSµ) pathway and TGFβ pathway are under investi-
gation (Berardi et al., 2014). The cell therapy approach is devoted
to functionally rescue the tissue through cell delivery; so far, in
place of muscle satellite cells, other cells isolated from embry-
onic (Filareto et al., 2013) and adult [pericytes, bone marrow,
mesangioblasts (Ferrari et al., 1998; Gussoni et al., 1999; Sam-
paolesi et al., 2006; Dellavalle et al., 2011)] sources or induced
pluripotent stem (iPS) cells (Darabi et al., 2012; Tedesco et al.,
2012) have been shown to contribute to muscle regeneration.
However, except for embryonic cells, a real integration of admin-
istered cells in muscle niche has barely been observed. Recently,
mesenchymal stem cells (MSCs) from human fetal blood (Chang
et al., 2006) and skeletal muscle progenitors from mouse embryo
(Sakai et al., 2013) have been used in muscle regeneration. Sev-
eral studies demonstrated that fetal tissues are abundant sources
of MSCs, including term placenta, fetal bone marrow, blood,
lung, liver, and spleen (in ‘t Anker et al., 2003; Fukuchi et al.,
2004), but the most available and easy sources to obtain fetal
stem cells are placenta, cord blood, Wharton’s jelly, and amniotic
fluid (AF).
FETAL STEM CELLS AND MUSCLE REGENERATION
Research on fetal stem cells and muscle is quite recent. Placenta,
cord blood, and AF represent an easy source of stem cells without
ethical concerns and are immune-privileged tissues (Toda et al.,
2007; Wang et al., 2009; Di Trapani et al., 2013). Placenta has been
primarily used as a membrane to treat burns, injuries, and skin
ulcers (Bujang-Safawi et al., 2010) and it has been studied also
to treat lung fibrosis (Cargnoni et al., 2009) and inflammatory
corneal diseases (Dekaris and Gabric, 2009). Cord blood has been
considered mainly as a source of hematopoietic cells (Cairo and
Wagner, 1997), although new field of applications such as dia-
betes are open (Zhao et al., 2012). Amniotic fluid stem (AFS) cells
recently found applications from the heart (Bollini et al., 2011) to
the kidney (Rota et al., 2011) and the lung (Carraro et al., 2008).
This review will evaluate the use of cells from the above men-
tioned sources in muscle regeneration (Table 1), focusing on both
the limits and future potential for therapy.
CORD BLOOD ANDWHARTON’S JELLY CELLS
Umbilical cord connects the fetus to the placenta; it develops from
the body stalk of the embryo and contains blood vessels and Whar-
ton’s jelly, surrounded by the amnion. Umbilical cord blood (UCB)
supplies the developing fetus of nutrients and oxygen through the
umbilical vein.
Umbilical cord blood possesses three main types of stem cells
that are of interest in regenerative medicine: (1) hematopoietic
stem cells, (2) MSCs, and (3) non-hematopoietic multipotent stem
cells characterized by the expression of SSEA-4, the transcription
factors OCT4, SOX2, and NANOG usually expressed by pluripo-
tent stem cells (McGuckin et al., 2005, 2008; Kucia et al., 2007;
Zuba-Surma et al., 2009). The blood vessels of the cord blood
are insulated with the gelatinous connective tissue called Whar-
ton’s jelly that prevents vein compression (Ferguson and Dodson,
2009). The cells isolated from this biological source share proper-
ties with MSCs from UCB such as differentiation ability (Anzalone
et al., 2010). Upon in vitro muscle differentiation, CD105+ cells
form Wharton’s jelly have been injected in injured ratTibialis ante-
rior muscle and after 15 days a mild muscle regeneration has been
detected (Conconi et al., 2006).
The involvement of UCB in therapeutic application was
reported since 1972, when clinicians treated one case of lym-
phoblastic leukemia (Ende and Ende, 1972). Nowadays, the trans-
lational potential of the clinical applications of UCB stem cells is
increased due to important advantages such as the ease to recover
the cells right after birth without any risk for the donor, the lack of
ethical issues, the low onset of graft-versus-host disease (GVHD)
(Broxmeyer et al., 1989; Ballen, 2005; Schoemans et al., 2006; Brun-
stein et al., 2007; Hwang et al., 2007; Broxmeyer, 2010), and finally
the high proliferation rate and long telomere maintenance (Kim
et al., 1999; Pipes et al., 2006). Starting from 2003, Pesce and
co-workers demonstrated muscle amelioration after injection of
CD34+ UCB cells in injured adductor muscle and new MYOD+
cells of UCB origin (Pesce et al., 2003) in a CD1 mouse model
of hindlimb ischemia. Later, in 2007, Koponen and colleagues,
using ischemia damage in the immunocompromised BALB/cA-nu
mouse, analyzed both endothelium and muscle after local injec-
tion of several cell types, namely UCB CD133+, CD34+, MSCs,
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Table 1 | Different fetal stem cells displayed myogenic differentiation ability.
Perinatal sources Mouse model/injury Engraftment Reference
HUMAN ORIGIN
UCB (CD34+) Sjl-Disf Yes, 12 weeks post injection Kong et al. (2004)
UCB (MSCs, CD133+) Balb/cA-nu: hindlimb ischemia
damage
No Koponen et al. (2007)
UCB (MSCs) Mdx Yes, Dys+ fibers 45 days post local injection Nunes et al. (2007)
UCB (CD34+) CD1: hindlimb ischemia damage MyoD+ cells Pesce et al. (2003)
Wharton’s jelly Lewis rat: bupivacaine injury Yes, 15 days post local injection Conconi et al. (2006)
Placenta In vitro only Lentiviral transfection with MyoD Akizawa et al. (2013)
Placenta SCID/mdx Yes, 4 weeks post injection Kawamichi et al. (2010)
Placenta (CD146+, CD34+,
CD146− CD34−)
SCID/mdx Yes, 4 weeks post injection Park et al. (2010)
AF c-Kit cells SCID No Gekas et al. (2010)
AFS cells BALB/cSlc-nu Yes, 21 days post injection Kim et al. (2013)
AFS cells NOD/SCID Yes, 4 weeks post injection Ma et al. (2012)
MOUSE ORIGIN
AFS cells HSA-Cre, SmnF7/F7 Yes, 1 and 15 month post injection and after
secondary transplant
Piccoli et al. (2012)
VEGF-D, or eGFP transduced cells, highlighting that the skeletal
muscle regeneration was an indirect effect of cytokines, such as
VEGF and FGF, released by the injected progenitor cells (Koponen
et al., 2007).
In the mdx mouse, Nunes and colleagues were able to find
a small number of human dystrophin-positive fibers 45 days after
injection of CD34+ UCB cells in quadriceps muscle. In the murine
model of LGMD-2B, the SJL-Dysf mouse, whole UCB, and CD34±
subgroups are engrafted in muscles after systemic injection (Nunes
et al., 2007), and expression of dysferlin and human dystrophin
was detected 12 weeks post injection of different subpopulation of
UCB cells, although in a small amount (Kong et al., 2004).
PLACENTA STEM CELLS
The placenta develops at the feto-maternal interface and is a
temporary organ that grows during pregnancy. It is formed by
fetal (amnion and chorionic plate) and maternal (decidua) por-
tions and contains different types of cells. Indeed, the placenta
is rich in stem/progenitor cells. While in the amnion human
amniotic epithelial cells, which express embryonic stem cell mark-
ers, have been isolated (epiblast-derived pluripotent/multipotent
stem cells) (Prusa and Hengstschlager, 2002; Miki et al., 2005,
2007), the placenta MSCs have been separated not only from
amnion, but also chorion and decidua (Huang et al., 2009; Poz-
zobon et al., 2014). These cells share with the adult MSCs the
spindle-shape appearance and the property to adhere to plastic
and to expand. Moreover, placenta MSCs expand faster in vitro
and are more immunosuppressive and less immunogenic than the
adult MSCs (Battula et al., 2008; Brooke et al., 2008). Recently,
a specific subgroup of cells isolated from the human placenta
villi and relevant for muscle regeneration, namely the perivascular
multipotent mesenchymal progenitor cells, have been character-
ized by Park et al. (2010). In this research, they studied the
angiogenic and myogenic potential of the CD146+ CD45− CD34−
CD56− cells (pericytes fraction) and CD146− CD45− CD34−
CD56− cells (non-pericytes fraction). When these cell populations
were intramuscularly implanted into damaged Gastrocnemius of
immunodeficient dystrophic mice, fibers positive for human dys-
trophin were found at the periphery of the damaged area. The
combination of perivascular progenitors together with the multi-
potent MSCs isolated from the placenta enhanced the migration
and regeneration capacity of the placenta stem cells demonstrating
that this extra-embryonic tissue is a reservoir of stem/progenitor
cells with myogenic potential. The in vitro myogenic differentia-
tion of cells from chorionic plate has been recently documented
(Kawamichi et al., 2010) using a standard chemical treatment
of inducing myoblasts formation (5-azacytidine) and also forc-
ing MYOD expression through a lentiviral vector (Akizawa et al.,
2013). Kawamichi and colleagues proved also the in vivo ability
of placenta-derived cells to ameliorate the dystrophic phenotype
of mdx mice inducing the appearance of newly formed fibers
expressing human dystrophin.
AMNIOTIC FLUID STEM CELLS
Amniotic fluid contains a heterogeneous population of cells dis-
playing a wide range of morphologies. Most of these cells are
epithelial in nature and have a limited capacity to proliferate in
culture. Traditionally, AF has been used for decades as a tool
for prenatal diagnosis, but recent studies provided important evi-
dences about the potential of AF as an alternative source of stem
cells. Many works have characterized putative stem cell popula-
tions isolated from AF, such as Prusa et al. (2003) that showed
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the expression of OCT4 within a subset of AF cells. Moreover,
demonstration of proliferation within this population suggests
that pluripotent stem cells can be isolated and propagated from
the human AF.
Employing immunoselection technique, AF cells expressing the
cell surface antigen c-Kit were purified from primary amniocente-
sis cultures (De Coppi et al., 2007). Isolated cells, called AFS cells,
grew rapidly in culture, display a normal karyotype and main-
tain telomere length during long-term culture. This latter attribute
facilitated the establishment of clonal lines from AFS cells, neces-
sary to establish the “stemness” of a population. Clonal AFS cell
lines differentiated in vitro to putative adipocytes, endothelial cells,
hepatocytes, osteocytes, myocytes, and neurons, derivatives of all
germ layers. This broad plasticity appeared to be a general attribute
of the selected cells: 19 different amniocentesis cultures yielded
multipotent AFS cell clonal lines. A subsequent report demon-
strated the AFS cells in vitro chondrogenic differentiation thus
providing further evidence of the plasticity and clinical potential
of cells isolated from the AF (Preitschopf et al., 2012). Moreover,
these cells displayed the ability to reconstitute the depleted bone
marrow of Rag1−/− mice after systemic injection and secondary
transplantation (Ditadi et al., 2009).
Another peculiar characteristic of AFS cells is indeed the ability
to pass through the endothelial barrier, thus they can be adminis-
tered locally or systemically, which represents a great advantage in
treating whole body diseases such as muscle dystrophies. Con-
sidering this important aspect, mouse AFS cells were used in
the HSA-Cre, SmnF7/F7 mouse model by transplantation via tail
vein (Piccoli et al., 2012). After injection, AFS cells demonstrated
remarkable ability to differentiate directly in vivo into myogenic
cells but most importantly were able to generate new muscle fibers
after cardiotoxin injury or secondary transplant, suggesting the
idea that AFS cells are capable of differentiating also in skeletal
muscle stem cells repopulating the muscle niche. In this work, the
use of freshly isolated or expanded murine AFS cells generated
similar results, but it is worth noticing that, with human AFS cells,
muscle lineage differentiation becomes difficult to obtain after
in vitro expansion. Gekas and colleagues indeed, did not find any
myogenic differentiation of human AF c-Kit+ cells after trans-
plantation into the skeletal muscle of SCID mice (Gekas et al.,
2010). Myogenic differentiation of AF cells can be induced in vitro
by DNA demethylation (e.g., using chemicals such as 5-aza-2′-
deoxycytidine), co-culture with myoblasts or myogenic cell lines,
or directly with in vivo muscle transplantation (De Coppi et al.,
2007; Gekas et al., 2010; Ma et al., 2012; Yang et al., 2012), but
all these approaches result in the induction of MYOD expression.
In fact, by transfecting human AFS cells with MYOD lentivirus,
Kim and co-workers demonstrated that human cells also were
able to differentiate into myogenic lineage in vitro and in vivo, after
injection into injured muscles of immunodeficient BALB/cSlc-nu
mice (Kim et al., 2013). All these data indicate that stem cells
obtained from discarded AF could be considered good candidates
for deeper research and investigation on their ability to differen-
tiate into myogenic cells. Further analyses must be performed to
make these cells more committed and at the same time safe for
future clinical applications using, for instance, non-viral system
such as Piggy Bac or Sleeping Beauty transposons (Izsvak et al.,
2009). These tools allow modifying cells by inserting new genes,
ensuring a constitutive genetic integration of the insertion and
opening possible way to cure genetic defects.
CONCLUSION
Muscle pathologies are devastating diseases and nowadays
researchers still make efforts to find a cure and not a therapy
alone. It has been demonstrated that, after injection in injured or
diseased muscle, fetal stem cells act through a mechanism that is
mostly due to a bystander effect rather than a direct differentiation.
The indirect action is mainly supposed to enhance the production
of cytokines, such as VEGF, that stimulate the temporary restor-
ing of the tissue function. To obtain a long lasting action due to
efficient cell integration and tissue repopulation, fetal stem cells
need to be genetically modified, forcing their differentiation in
tissue-specific cells. Nevertheless, the development of safe genetic
manipulation methods could make cells of fetal origin appealing
for therapeutic application.
Conversely, the long-term positive effect observed using freshly
isolated murine AFS cells, highlights that they could have a decisive
role in replenishing the muscle stem cell niche, which represent
the reservoir of cells able to rescue the defect. Indeed, AFS cells
are a safe and immune-privileged cell source prone to integrate
in muscle tissue. This knowledge opens the challenge to improve
the culture protocol for the AFS cells of human origin, which, so
far, is still a limit to overcome for future clinical application to
treat genetic and non-genetic muscle dysfunctions (dystrophies,
skeletal muscle malformations, traumatic injuries).
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